APR-246/eprenetapopt has been tested or is tested in thirteen clinical trials (clinicaltrials.gov, accessed 10.09.2023) in cancer and is, so far, the most clinically advanced and promising drug reactivating mutant p53 in myeloid malignancies to date. The gene discussed is TP53; the disease is myeloid neoplasm.